Cure8 news brief
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study focused on whether strictures become endoscopically passable.
That could matter for symptom relief and avoiding dilation or surgery if confirmed in controlled trials.
Adults with fibrostenosing Crohn’s disease, patients interested in emerging anti‑fibrotic IBD treatments, clinicians who treat stricturing Crohn’s, and researchers in drug development for IBD strictures.
This is an industry SEC filing summarizing open‑label extension (OLE)
These are OLE and filing summaries from the company’s SEC 6‑K; OLE results are uncontrolled and evaluable‑patient remission percentages can overstate effect compared with randomized controlled data. Ontunisertib is investigational; safety and efficacy are not established. The NOV‑ERA trial is planned but not yet read out.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
